Antisense Technology

DNA Therapy for Small Cell Lung Cancers Expressing L-myc

Published in Cancer Weekly, May 8th, 1995

Recent research determines that the L-myc gene is a good target gene for antisense DNA therapy based on its molecular biological diagnosis in human small cell lung cancer (SCLC).

A study by Hirotoshi Dosaka-Akita et al. demonstrated that the exposure of human SCLC cell lines overexpressing the L-myc gene to an L-myc antisense oligodeoxynucleoside phosphorothiote (OPT) which covered the translational initiation site of the L-myc protein inhibited cell proliferation ("Inhibition of Proliferation by L-myc Antisense DNA for the Translational Initiation Site in Human Small Cell Lung Cancer," Cancer Research, April 1, 1995;55(7):1559-1564).

...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (1995-05-08)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry